Related Experiment Video
Updated: Apr 15, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.5K
Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase
Nuno Miguel Pires1, Bruno Igreja1, Eduardo Moura1
1Department of Research & Development, BIAL-Portela & Ca, S.A., S. Mamede do Coronado, Portugal.
Summary
Renal denervation provided temporary blood pressure reduction in rats, while inhibiting dopamine β-hydroxylase (DβH) with etamicastat offered sustained blood pressure control by reducing noradrenaline levels.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Nephrology
Background:
- Sympathetic nervous system overactivity contributes to arterial hypertension.
- Renal denervation (RDN) is a new treatment for drug-resistant hypertension.
- Inhibiting dopamine β-hydroxylase (DβH) offers an alternative to modulate sympathetic nerve function.
Purpose of the Study:
- To compare the effects of RDN and DβH inhibition on blood pressure and sympathetic nerve activity.
- To evaluate the long-term efficacy of etamicastat, a DβH inhibitor, versus RDN in hypertensive rats.
Main Methods:
- Spontaneously hypertensive rats (SHR) underwent RDN or received etamicastat (30 mg/kg/day).
- Blood pressure, renal function, and noradrenaline (NA) levels were monitored over 28 days.
- Water balance, renal function, and urinary electrolytes were assessed.
Main Results:
- Both RDN and etamicastat did not affect renal function.
- RDN temporarily reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP).
- Etamicastat significantly decreased SBP and DBP throughout the study period.
- NA levels decreased in renal tissue for both groups; only etamicastat reduced left ventricle NA.
Conclusions:
- RDN provides transient blood pressure reduction.
- Sustained sympathetic inhibition via DβH inhibition with etamicastat leads to prolonged blood pressure lowering.
- Etamicastat presents a promising therapeutic strategy for sustained hypertension management.
More Related Videos
05:57Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
1.3K
11:08Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
Published on: February 14, 2018
11.2K
Related Concept Videos
01:18Hypertension and Regulation of Blood Pressure
4.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.8K
01:17Antihypertensive Drugs: Action of β1 Blockers
2.3K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.3K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
01:29Hypertension II: Pathophysiology
1.6K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.6K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K